DES MOINES – Last Friday the Iowa Department of Public Health issued a notice of intent to award a second license to manufacture medical cannabidiol in Iowa to Iowa Relief. The Cedar Rapids-based company will be required to begin serving Iowa’s dispensaries by July 1, 2019. MedPharm Iowa was awarded a license to manufacture in November 2017, and is required to start supplying products to state-licensed dispensaries by December 2018.
Since receiving its license to manufacture medical cannabidiol in the state, MedPharm Iowa has been an advocate for those dealing with chronic pain, cancer and debilitating medical conditions who are seeking natural, scientifically proven solutions. MedPharm Iowa has appealed to state legislators to remove the three percent cap on tetrahydrocannabinol (THC) and expand the list of qualified medical conditions. These changes would allow Iowa’s medical cannabidiol program to better serve a greater number of patients, but the legislature chose not to strengthen the quality of the state’s medical cannabidiol program during the 2018 session.
“We look forward to having Iowa Relief join MedPharm Iowa as a manufacturer and fellow advocate for Iowa patients and an improved medical cannabidiol program,” said Dr. Chris Nelson, owner of MedPharm Iowa. “As the program stands today, though, with its restrictive laws, it will not serve Iowans as intended. We hope that, together with Iowa Relief, we can provide qualified Iowans with the products they need and continue to champion a more inclusive, effective program that improves the quality of life for all those impacted.”
In addition to manufacturing medical cannabidiol products, MedPharm Iowa will operate dispensaries in Sioux City and Windsor Heights, a suburb of Des Moines. This will give MedPharm Iowa the opportunity to interact directly with patients, gather deeper insights into their needs, and alter or develop products to best suit their treatment needs and forms of delivery.